title: New therapy targets resistant non-small-cell lung cancers.
authors.forename: Susan
authors.initials: S
authors.lastname: Jenks
mesh_terms: D000077716:Afatinib; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology* / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000378:metabolism; D000068818:Cetuximab; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D066246:ErbB Receptors / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D058990:Molecular Targeted Therapy / Q000379:methods*; D054547:National Cancer Institute (U.S.); D011799:Quinazolines / Q000008:administration & dosage / Q000494:pharmacology; D014481:United States
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D004338:Drug Combinations; D011799:Quinazolines; D000077716:Afatinib; D000069347:Erlotinib Hydrochloride; C512478:EGFR protein, human; D066246:ErbB Receptors; D000068818:Cetuximab; D000077156:Gefitinib